Mineralys Therapeutics, Inc. (MLYS) Misses Q4 EPS by 27c

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) reported Q4 EPS of ($0.98), $0.27 worse than the analyst estimate of ($0.71).

For earnings history and earnings-related data on Mineralys Therapeutics, Inc. (MLYS) click here.

You May Also Be Interested In

• Calumet Specialty Products Partners (CLMT) PT Raised to $47 at UBS
• Canada Puts 15% To 50% Tariffs On About $20b Of US Products - Bloomberg
• NVIDIA (NVDA) call put ratio 2.8 calls to 1 put into quarter results